Synonym
TQB3616; TQB-3616; TQB 3616
IUPAC/Chemical Name
5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)-N-(5-(piperazin-1-yl)pyridin-2-yl)pyrimidin-2-amine
InChi Key
LLFOBMRPWNABCB-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H27FN8/c1-15(2)23-18-12-16(4-6-20(18)31-32(23)3)22-19(25)14-28-24(30-22)29-21-7-5-17(13-27-21)33-10-8-26-9-11-33/h4-7,12-15,26H,8-11H2,1-3H3,(H,27,28,29,30)
SMILES Code
FC1=CN=C(N=C1C2=CC3=C(C(C)C)N(C)N=C3C=C2)NC(N=C4)=CC=C4N5CCNCC5
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
446.53
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Hu W, Wang L, Luo J, Zhang J, Li N. The Potent Novel CDK4/6 Inhibitor TQB3616
in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in
vitro and Human Tumor Xenograft Models. Breast Cancer (Dove Med Press). 2023 Dec
8;15:899-912. doi: 10.2147/BCTT.S434973. PMID: 38090281; PMCID: PMC10715022.
2: Xu Z, Liu Y, Song B, Ren B, Xu X, Lin R, Zhu X, Chen C, Yang S, Zhu Y, Jiang
W, Li W, Xia Y, Hu L, Chen S, Chan CC, Li J, Zhang X, Yang L, Tian X, Ding CZ.
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Bioorg Med Chem Lett. 2024 Jul 15;107:129769. doi: 10.1016/j.bmcl.2024.129769.
Epub 2024 Apr 24. PMID: 38670537.
3: Wardoyo S, Fadillah MA, Hamtini. The Potent Novel CDK4/6 Inhibitor TQB3616 in
Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in
vitro and Human Tumor Xenograft Models [Letter]. Breast Cancer (Dove Med Press).
2023 Dec 19;15:953-954. doi: 10.2147/BCTT.S454296. PMID: 38143481; PMCID:
PMC10748707.